SEC Tracker
Get the app

First Wave BioPharma GRDX

First Wave BioPharma FY 2023: net loss $15.8M; diluted EPS −$149,000.54

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 4.31
Warrants or notes
Exhibit 10.53
Material contract

Key figures from this report

These are the numbers First Wave BioPharma reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$15.8MAgainst −$14.6M in FY 202210-K income statement, on EDGAR
  2. Diluted EPS−$149,000.54Against −$9,152,817.38 in FY 2022. Split-adjusted, as the tables show it; the filing reported −$47.8810-K income statement, on EDGAR
  3. Cash and cash equivalents$3.7M+172% from $1.4M in FY 202210-K balance sheet, on EDGAR
  4. Cash from operations−$12.4MAgainst −$22.3M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when First Wave BioPharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 4931 and related industry codes: the same peer list as the financial tables.

  1. OPAL Fuels OPAL public float $65M, Jun 30, 2025
  2. Aedis Energy ADIS public float $2M, Jun 30, 2025
  3. Genie Energy GNE public float $512M, Jun 30, 2025
  4. Unitil UTL public float $833M, Jun 30, 2025
  5. Ocean Thermal Energy CPWR public float $181K, Jun 30, 2025